Back

User Preferences on Long-Acting Pre-Exposure Prophylaxis for HIV Prevention in Sub-Saharan Africa: A Scoping Review

Pfau, B. A.; Saravis, A.; Cox, S.; Wu, L.; Wittenauer, R.; Callen, E.; Arrouzet, C.; Sharma, M.

2024-04-02 hiv aids
10.1101/2024.04.01.24305173 medRxiv
Show abstract

Structured AbstractO_ST_ABSBackgroundC_ST_ABSNovel formulations for PrEP such as injectables, implants, and intravaginal rings are emerging as long-acting alternatives to daily pills for the prevention of HIV. Sub-Saharan Africa has the highest HIV burden as well as the highest PrEP coverage globally. As long-acting formulations continue to become available, it is crucial to understand the product preferences of potential users. ObjectiveTo conduct a scoping review focused on the region of Sub-Saharan Africa to understand which PrEP products, especially long-acting formulations, different patients and demographic groups prefer as well as the factors that influence their preferences. DesignWe identified 34 publications published between 2014 and 2024 that assessed preferences regarding at least one long-acting PrEP product in the region of Sub-Saharan Africa. ResultsParticipants preferred longer-acting products over oral pills when given the choice in almost all studies. On-demand PrEP was commonly preferred over daily dosing, and long-acting products were preferred over on-demand dosing. A majority of studies found injectables to be most commonly preferred compared to daily oral PrEP, implants, and rings. This preference was observed across a range of demographics including men and women, youth, men who have sex with men, and female sex workers. Duration, efficacy, and discretion were the three most important factors influencing participants choices. ConclusionsLong-acting products, especially injectables, are acceptable for a wide range of individuals at risk of HIV in Sub-Saharan Africa and tend to be preferred over daily oral pills. Participants expressed a diversity of values and opinions regarding preferences, emphasizing the benefit of providing multiple formulations to maximize coverage over heterogeneous populations. Strength and Limitations of this StudySome key populations, such as transgender women, were underrepresented in the literature. With most studies published before long-acting products became widely available, the hypothetical preferences of non-experienced users may differ from preferences in practice.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Journal of the International AIDS Society
20 papers in training set
Top 0.1%
21.5%
2
BMJ Open
554 papers in training set
Top 0.9%
17.8%
3
PLOS ONE
4510 papers in training set
Top 20%
9.6%
4
AIDS and Behavior
14 papers in training set
Top 0.1%
6.1%
50% of probability mass above
5
PLOS Medicine
98 papers in training set
Top 0.6%
6.1%
6
BMJ Global Health
98 papers in training set
Top 0.6%
6.0%
7
JAIDS Journal of Acquired Immune Deficiency Syndromes
19 papers in training set
Top 0.2%
4.6%
8
Sexually Transmitted Infections
21 papers in training set
Top 0.2%
2.9%
9
AIDS
31 papers in training set
Top 0.2%
2.8%
10
Nature Human Behaviour
85 papers in training set
Top 1%
2.8%
11
BMC Public Health
147 papers in training set
Top 3%
1.8%
12
JAMA Network Open
127 papers in training set
Top 2%
1.6%
13
Open Forum Infectious Diseases
134 papers in training set
Top 2%
1.4%
14
The Lancet Global Health
24 papers in training set
Top 0.8%
1.2%
15
PLOS Global Public Health
293 papers in training set
Top 5%
1.1%
16
Journal of Medical Internet Research
85 papers in training set
Top 4%
0.9%
17
International Journal of Environmental Research and Public Health
124 papers in training set
Top 6%
0.9%
18
Tropical Medicine and Infectious Disease
12 papers in training set
Top 0.4%
0.9%
19
Pilot and Feasibility Studies
12 papers in training set
Top 0.5%
0.9%
20
eClinicalMedicine
55 papers in training set
Top 2%
0.7%
21
Clinical Infectious Diseases
231 papers in training set
Top 5%
0.6%